Financials in USD. Standardized financial statements.
A compact view of how EyePoint Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $31.37M | $43.27M | $46.02M | $41.40M | $36.94M | $34.44M | $20.36M | $2.96M | $7.54M | $1.62M |
| Revenue Growth? | -27.5% | -6.0% | +11.1% | +12.1% | +7.3% | +69.1% | +587.8% | -60.7% | +365.4% | 0.0% |
| Cost of Revenue? | $2.07M | $3.71M | $4.63M | $8.33M | $8.18M | $5.82M | $2.69M | $18.50M | $0 | $815,000 |
| Gross Profit? | $29.30M | $39.56M | $41.39M | $33.08M | $28.76M | $28.61M | $17.68M | -$15.54M | $7.54M | $805,000 |
| Gross Margin? | +93.4% | +91.4% | +89.9% | +79.9% | +77.9% | +83.1% | +86.8% | -524.9% | +100.0% | +49.7% |
| Operating Expenses? | $272.74M | $185.41M | $116.45M | $132.72M | $84.04M | $65.90M | $65.54M | $29.23M | $26.11M | $23.39M |
| Operating Income? | -$243.43M | -$145.85M | -$75.07M | -$99.64M | -$55.28M | -$37.29M | -$47.86M | -$26.27M | -$18.58M | -$21.77M |
| EBITDA? | -$243.43M | -$129.23M | -$69.00M | -$96.62M | -$50.15M | -$35.49M | -$48.01M | -$36.99M | -$18.58M | -$17.67M |
| Income Before Tax | -$231.68M | -$130.78M | -$70.71M | -$102.25M | -$58.42M | -$45.39M | -$56.79M | -$53.17M | -$18.48M | -$21.70M |
| Income Tax Expense | $279,000 | $90,000 | $83,000 | $0 | $0 | $0 | $0 | -$25.56M | -$815,000 | -$155,000 |
| Net Income? | -$231.96M | -$130.87M | -$70.80M | -$102.25M | -$58.42M | -$45.39M | -$56.79M | -$53.17M | -$18.48M | -$21.55M |
| EPS? | $-3.17 | $-2.32 | $-1.82 | $-2.74 | $-2.03 | $-3.54 | $-6.04 | $-11.50 | $-5.23 | $-6.81 |
| Diluted EPS? | $-3.17 | $-2.32 | $-1.82 | $-2.74 | $-2.03 | $-3.54 | $-6.04 | $-11.50 | $-5.23 | $-6.81 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality